Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Forced Transdifferentiation01:28

Forced Transdifferentiation

1.9K
Transdifferentiation, also known as lineage reprogramming, was first discovered by Selman and Kafatos in 1974 in silkmoths. They observed that the moths’ cuticle-producing cells transformed into salt-producing cells. Many such cases of natural transdifferentiation occur in organisms. In humans, pancreatic alpha cells can become beta cells. In newts, the loss of the eye’s lens causes the pigmented epithelial cells to transdifferentiate into the lens cells.
Artificial...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiscale analysis and functional validation of the cellular and genetic determinants of skeletal disease.

Nature genetics·2026
Same author

Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myeloma.

HemaSphere·2026
Same author

Multiple myeloma: A tale of deregulated transcription factors.

HemaSphere·2026
Same author

Stromal and endothelial transcriptional changes during progression from MGUS to myeloma and after treatment response.

Nature communications·2026
Same author

Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencing.

HemaSphere·2026
Same author

Monomethyl-auristatin E-based anti-CD137 (4-1BB) antibody drug conjugates are not suitable tools to deplete activated T lymphocytes.

Immunobiology·2026

Related Experiment Video

Updated: Jun 22, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

73

Epigenetic-based differentiation therapy for Acute Myeloid Leukemia.

Edurne San José-Enériz1,2, Naroa Gimenez-Camino1,2, Obdulia Rabal3

  • 1Hemato-Oncology Program, Center for Applied Medical Research (CIMA), Universidad de Navarra, IDISNA, CCUN, Avenida Pío XII 55, 31008, Pamplona, Spain.

Nature Communications
|July 2, 2024
PubMed
Summary

Two novel lysine deacetylase inhibitors, CM-444 and CM-1758, effectively promote myeloid differentiation in all acute myeloid leukemia subtypes at low doses. These compounds offer a promising new avenue for acute myeloid leukemia treatment by targeting key differentiation pathways.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K
In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.2K

Related Experiment Videos

Last Updated: Jun 22, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

73
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K
In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.2K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Acute myeloid leukemia (AML) outcomes remain poor despite novel therapies, highlighting an urgent need for improved treatments.
  • Differentiation-inducing therapies are successful in acute promyelocytic leukemia but require exploration in other AML subtypes.

Purpose of the Study:

  • To identify and characterize novel agents that promote myeloid differentiation across all AML subtypes.
  • To investigate the mechanism of action of these agents, focusing on epigenetic modifications.

Main Methods:

  • Screening and characterization of lysine deacetylase inhibitors (CM-444 and CM-1758).
  • Assessment of myeloid differentiation induction in AML cell lines at low, non-cytotoxic doses.
  • Acetylome analysis to identify protein targets and pathways modulated by the inhibitors.

Main Results:

  • CM-444 and CM-1758 demonstrated the capacity to induce myeloid differentiation in all tested AML subtypes.
  • These inhibitors were effective at low, non-cytotoxic concentrations, distinguishing them from commercial histone deacetylase inhibitors.
  • Treatment modulated acetylation of non-histone proteins within the enhancer-promoter regulatory complex, including bromodomain proteins.

Conclusions:

  • CM-444 and CM-1758 represent potential differentiation-based therapeutic agents for a broad range of acute myeloid leukemia subtypes.
  • The mechanism involves acetylation of key regulatory proteins, enhancing transcription factors essential for differentiation therapy.
  • These findings suggest a promising new strategy for treating acute myeloid leukemia.